Can ACTC’s Stem Cells be Used to Treat Severe Myopia?
February 19, 2013
Advanced Cell Technology, Inc. (OTCBB: ACTC) announced last week that one of its clinical trial partners, UCLA’s Jules Stein Eye Institute, has received FDA approval of its Investigational New Drug (IND) Application to initiate a Phase I/II study using ACTC’s retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat severe myopia (commonly known as nearsightedness).
The primary focus of the study will be to evaluate the safety in patients with severe myopia of the type that causes fissures in the RPE layer of the eye. The evaluation of ACT’s RPE cells in potentially treating severe myopia is an expansion of ACTC’s current trials of using stem cells to treat Stargardt’s disease and macular degeneration.
Click here to read the full release.
Comments
Jump down to form below to submit your own comments
